CIPRO XR Drug Patent Profile

Which patents cover Cipro Xr, and when can generic versions of Cipro Xr launch?

Cipro Xr is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in CIPRO XR is ciprofloxacin; ciprofloxacin hydrochloride. There are thirty-four drug master file entries for this compound. Additional details are available on the ciprofloxacin; ciprofloxacin hydrochloride profile page.

Summary for CIPRO XR

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CIPRO XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	CIPRO XR	ciprofloxacin; ciprofloxacin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021473-001	Dec 13, 2002		DISCN	No	No
Bayer Hlthcare	CIPRO XR	ciprofloxacin; ciprofloxacin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021473-002	Aug 28, 2003		DISCN	No	No

International Patents for CIPRO XR

See the table below for patents covering CIPRO XR around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	360632
Ireland	812032
Morocco	25761
Cyprus	1301	7-AMINO-1-CYCLOPROPYL-4-OXO-1,4-DIHYDRO-NAPHTHYRIDINE(-QUINOLINE)-3-CARBOXYLIC ACIDS,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Austria	355062

Last updated: February 3, 2026

vestment Scenario and Fundamentals Analysis for CIPRO XR

Overview
CIPRO XR (ciprofloxacin extended-release) is a broad-spectrum fluoroquinolone antibiotic approved by the FDA for treating urinary tract infections and prostatitis. Produced by Bayer, its patent expired in 2017, leading to increased generic competition. Its market presence now depends heavily on its formulary status, provider prescribing patterns, and evolving antibiotic resistance.

Market Context
The global antibiotic market is valued at over $50 billion annually, with fluoroquinolones representing a significant share. CIPRO XR's sales peaked in the early 2000s; however, usage has declined in recent years due to safety concerns, especially risks of tendinopathy, neuropathy, and QT prolongation. The declining prescription trend affects its long-term revenue potential.

Regulatory and Patent Landscape
CIPRO XR's patent protection ended in 2017, allowing generics to enter the market. Generic ciprofloxacin formulations now dominate, contributing to a sharp price decline. Bayer maintains a patent on an extended-release formulation, but challenges from generic manufacturers and patent expiries diminish exclusivity.

Competitive Position
In the antibiotic space, CIPRO XR faces competition from newer agents such as fosfomycin and nitrofurantoin for urinary tract infections. These alternatives often have better safety profiles and lower resistance rates. Despite its broad efficacy, CIPRO XR's declining prescriber acceptance limits growth prospects.

Resistance Trends and Prescribing Dynamics
Global surveillance indicates increasing ciprofloxacin resistance in common pathogens like Escherichia coli, especially in community settings. Resistance rates have risen from below 10% in the early 2000s to over 20% in many regions, reducing the drug’s efficacy and desirability.

Financial and Investment Perspectives

Aspect	Details
Revenue Trends	Peaked at ~$400 million globally in 2004; declined >70% by 2022 due to generic competition and safety concerns.
Market Share	Dominant in early 2000s; now less than 10% among fluoroquinolones.
Licensing and Approvals	No recent new formulations or adjunct indications approved.
R&D and Pipeline	Bayer has shifted focus away from ciprofloxacin, investing in new antibiotics with novel mechanisms.
Price Point	Average price for generic ciprofloxacin (~$1-$3 per tablet), exerting continuous pressure on revenues.

Investment Risks

• Declining prescribing rates due to safety issues and resistance.
• Loss of exclusivity leading to price erosion.
• Regulatory shifts discouraging fluoroquinolone use.
• Competitive pressures from newer antibiotics with better safety profiles.

Opportunities

• Potential niche uses in multi-drug resistant infections if resistance trends plateau or decline.
• Opportunities for formulation enhancements or combination therapies.
• Geographic expansion in regions with limited access to newer antibiotics while resistance remains low.

Key Data Points

• Market share declined from approximately 35% in 2010 to under 10% in 2022 among fluoroquinolones (IMS Health, 2022).
• Resistance rates for E. coli urinary isolates in the US increased from 10% (2010) to 22% (2020) (CDC NARMS).
• Generic formulations outnumber original proprietary versions 20:1 post-2017 patent expiry (FDA Orange Book).
• Bayer's 2022 R&D budget allocated less than 2% to antibiotics, focusing on niche or novel drug development.

Conclusion

CIPRO XR's intrinsic value as a drug has diminished significantly. Market decline, generic competition, safety and resistance issues, and shifting prescribing patterns reduce its investment appeal. While niche opportunities may exist sporadically, the overall outlook indicates limited growth and declining revenue streams for traditional formulations.

---

Key Takeaways

• CIPRO XR's patent expiry and generic competition have led to erosion of market share and revenues.
• Growing resistance diminishes clinical utility, further impacting prescribing trends.
• Heavy regulatory and safety concerns limit future expansion, emphasizing its niche role.
• Investment considerations should focus on lifecycle management or novel formulations rather than core ciprofloxacin.
• The drug’s position in the broader antibiotic market indicates declining investment appeal absent strategic repositioning.

---

FAQs

1. What factors most influence CIPRO XR's market decline?
   Patent expiration, generic competition, safety concerns, and rising antibiotic resistance.

2. Are there opportunities for reinvestment or new formulations?
   Limited; Bayer has moved away from ciprofloxacin R&D, focusing on chemically novel antibiotics.

3. How does rising antibiotic resistance impact future sales?
   Resistance reduces efficacy, prompting prescribers to favor newer agents, further shrinking usage.

4. Is CIPRO XR still used in specific indications?
   Yes, primarily for certain urinary tract infections, but its prescribing is decreasing globally.

5. Would investments in CIPRO XR be justified now?
   No; the financial and competitive landscape suggests minimal upside and ongoing decline.

---

Citations
[1] IMS Health, "Global Antibiotic Market Report," 2022.
[2] CDC NARMS Antibiotic Resistance Data, 2020.
[3] FDA Orange Book, "Patent and Exclusivity Status," 2023.